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CASE

BACKGROUND

The patient is a 75 year-old female with a history of stage 1
invasive ductal carcinoma of the left breast measuring 1.2 cm.
Core biopsy of the mass demonstrated Nottingham grade 3
invasive ductal carcinoma; ER negative, PR negative, HER-2
negative (1+). The patient underwent mastectomy in April 2013.
Mastectomy confirmed Nottingham grade 3 invasive ductal
carcinoma pT1c/pN0/pMX with peritumoral lymphovascular
invasion and invasive tumor less than 1 mm from the
superoanterior margin. Due to comorbidities the patient was not
considered a candidate for adjuvant chemotherapy.
In January 2014 the patient presented with a mastectomy site
recurrence. Needle core biopsy confirmed recurrent Nottingham
grade 3 ductal carcinoma with papillary differentiation. ER and PR
remained negative. However, HER-2 immunohistochemistry
showed clear intratumoral heterogeneity. The percentage of total
tumor that the positive subclone represented was approximately
1%. The biopsy was vacuum-assisted, generous, and consisted
essentially entirely of invasive carcinoma without an in situ
component.
On low magnification the
HER-2 IHC studies
conducted on the core
biopsy of the mastectomy
site recurrence show a
largely HER-2 negative
tumor (score: 0/1+) with
small islands of positive
cells highlighted.

On higher magnification,
it is evident that the focal
proliferations of HER-2
positive cells are strongly
stained on IHC (score: 3+).

In situ hybridization of the
IHC positive subclones
confirmed HER-2
amplification (ISH amplified
areas shown on left,
non-amplified on right)

HER-2/neu (c-erbB-2) is a proto-oncogene located on
chromosome 17 (17q12-21.32) that codes for a 185-kDa
transmembrane protein of the epidermal growth factor receptor
family of tyrosine kinases. Overexpression of HER-2 is present in
around 25% of breast cancers. It promotes cell growth and division
and is associated with increased disease recurrence and poor
prognosis. Herceptin and related drugs are monoclonal antibodies
that bind to the extracellular domain of the receptor altering its
expression and effects by various mechanisms. When Herceptin
was developed it was generally accepted that tumors either
demonstrated HER-2 amplification or they did not. It was during
the continuing evolution in methodologies for assessing HER-2
status that the issue of tumor heterogeneity arose.

CURRENT ASCO/CAP GUIDELINES
- IHC: 10% complete circumferential membrane staining (3+)
- ISH (dual probe): HER-2:CEP17 ratio ≥ 2
- ISH (single probe): average HER-2 copy number ≥ 6/nucleus

DISCUSSION
Most breast cancer cases are uniform in their expression and
amplification of HER-2. Intratumoral heterogeneity has been
estimated to occur in 5-30% of HER-2 positive breast cancer cases.
Recent papers suggest it may be even more frequent, and that a
subset of these may benefit from HER-2 targeted therapy. This
begs the question of why a certain tumor, such as that presented in
this case, would be considered negative and ineligible for Herceptin
therapy despite containing HER-2 positive cells. In analyzing the
ASCO/CAP guidelines and modalities of determining HER-2
positivity (IHC and ISH), we discovered certain inconsistencies
which demonstrate that neither technique is yet definitive.
The HER-2:CEP17 ratio method for accounting for chromosome
17 polysomy was largely implemented before the extreme rarity of
this condition in breast cancer was appreciated. In cases where
ISH is conducted alone, tumors with ratios less than 2 may be the
ruled as negative due to CEP17 co-amplification with HER-2.
Additionally, traditional fluorescent in situ hybridization techniques

allow for good HER-2 signal discrimination but suffer from poor
visualization of the cells themselves, thus making it difficult to
discern tumor from non-tumor when counting amplified cells. ISH
also requires high magnification (600x -1000x) which makes
assessment of heterogeneity within an entire tumor prohibitively
demanding and time consuming. The major limitation of IHC is that
some tumors fall into the equivocal 2+ category and are
indeterminate without reflex ISH testing. The 10% cutoff in the
ASCO/CAP guidelines is similar to that used in most studies with
Herceptins, so little is known about the efficacy of monoclonal
antibody treatment against tumors with smaller HER-2 amplified
populations.

QUESTIONS FOR FURTHER STUDY
• Do treatment guidelines for Herceptin initiation need to be
altered in order to better account for patients with HER-2
heterogeneity?
• Is treatment without Herceptin a selective pressure for HER-2
proliferation in a heterogeneous tumor?
• Are there identifiable characteristics or markers which indicate
an increased likelihood of tumor evolution from HER-2 negativity
to positivity?
• Should HER-2 be re-assessed in biopsy-negative excision
specimens to more thoroughly search for heterogeneous
subpopulations?
• Would the more inclusive guidelines for HER-2 heterogeneous
gastric tumors be applicable in certain cases of breast cancer?

CONCLUSIONS
HER-2 tumor heterogeneity is increasingly recognized as an
unresolved issue in breast cancer that poses significant diagnostic
and therapeutic challenges. Our understanding of the process is
incomplete but continued work in this area holds promise not only
for more effective personalization of therapy, but for increasing our
understanding of tumor evolution in general.
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